Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2023 Oct 5;38(6):e20230015.
doi: 10.21470/1678-9741-2023-0015.

Safety, Effectiveness, and Hemodynamic Performance of the Bovine Pericardium Organic Valvular Bioprosthesis

Álvaro Machado Rösler  1 , Fernando Antonio Lucchese  1 , Pablo Maria Alberto Pomerantzeff  2 , Luiz Carlos Santana Passos  3
Affiliations
Clinical Trial

Safety, Effectiveness, and Hemodynamic Performance of the Bovine Pericardium Organic Valvular Bioprosthesis

Álvaro Machado Rösler et al. Braz J Cardiovasc Surg. .

Abstract

Objective: To assess actual data on the safety, effectiveness, and hemodynamic performance of Bovine Pericardium Organic Valvular Bioprosthesis (BVP).

Methods: The BIOPRO Trial is an observational, retrospective, non-comparative, non-randomized, and multicenter study. We collected data from 903 patients with symptomatic, moderate, or severe valve disease who underwent BVP implants in the timeframe from 2013 to 2020 at three Brazilian institutions. Death, valve-related adverse events (AEs), functional recovery, and hemodynamic performance were evaluated at the hospital, at discharge, and six months and one year later. Primary analysis compared late (> 30 days after implant) linearized rates of valve-related AEs, such as thromboembolism, valve thrombosis, major hemorrhage, major paravalvular leak, and endocarditis, following objective performance criteria (OPC). Analysis was performed to include at least 400 valve-years for each valve position (aortic and mitral) for complete comparisons to OPC. Kaplan-Meier survival and major adverse cardiovascular and cerebrovascular event analyses were also performed.

Results: This retrospective study analyzed follow-up data collected from 903 patients (834.2 late patient-years) who have undergone surgery for 455 isolated aortic valve replacement (50.4%), 382 isolated mitral valve replacement (42.3%), and 66 combined valve replacement or other intervention (7.3%). The linearized rates of valve-related AEs were < 2 × OPC. One-year survival rates were 95.1% and 92.7% for aortic and mitral valve replacement, respectively. This study demonstrated an improvement in the New York Heart Association classification from baseline and hemodynamic performance within an expected range.

Conclusion: According to this analysis, BVP meets world standards for safety and clinical efficacy.

Keywords: Animals; Aortic Valve; Bioprosthesis; Heart Valve Prosthesis; Hemodynamics; Prosthesis Design; Treatment Outcomes.

PubMed Disclaimer

Conflict of interest statement

No conflict of interest.

Figures

Fig. 1
Fig. 1
New York Heart Association classification of pre-procedure vs. post-procedure patients for different positions. AVR=aortic valve replacement; MVR=mitral valve replacement.
Fig. 2
Fig. 2
Hemodynamic results at one-year follow-up. AVR=aortic valve replacement; EOA=effective orifice area; MVR=mitral valve replacement.
Fig. 3
Fig. 3
Survival curve stratified by valve surgery. AVR=aortic valve replacement; MVR=mitral valve replacement.
Fig. 4
Fig. 4
Major adverse cardiovascular and cerebrovascular event (MACCE)-free rate in aortic valve replacement (AVR) and mitral valve replacement (MVR) patients.
S3
S3
Distribution of valve sizes implanted in the aortic position.
S4
S4
Distribution of valve sizes implanted in the mitral position.
S6
S6
Change in New York Heart Association classification from baseline.
S7
S7
Valve regurgitation in 1-year follow-up.
None
See this image and copyright information in PMC

References

    1. Singhal P, Luk A, Butany J. Bioprosthetic heart valves: impact of implantation on biomaterials. ISRN Biomaterials. 2013:1–14. doi: 10.5402/2013/728791. - DOI
    1. Ionescu MI, Wooler GH, Smith DR, Grimshaw VA. Mitral valve replacement with aortic heterografts in humans. Thorax. 1967;22(4):305–313. doi: 10.1136/thx.22.4.305. - DOI - PMC - PubMed
    1. Ionescu MI, Ross DN. Heart-valve replacement with autologous fascia lata. Lancet. 1969;2(7616):335–338. doi: 10.1016/s0140-6736(69)92696-8. - DOI - PubMed
    1. Bapat VN. The pericardial heart valve: the odyssey of a continuously evolving concept (1971-2014) [Internet] Society for Cardiothoracic Surgery in Great Britain and Ireland; c2014. pp. 133–133. [cited 2023 Mar 12]. Available from: https://www.ctsnet.org/news/pericardial-heart-valve-book-now-available-c....
    1. Tillquist MN, Maddox TM. Cardiac crossroads: deciding between mechanical or bioprosthetic heart valve replacement. Patient Prefer Adherence. 2011;5:91–99. doi: 10.2147/PPA.S16420. - DOI - PMC - PubMed

LinkOut - more resources